secwatch.observer — SEC 8-K summary
======================================

Issuer:     Voyager Therapeutics, Inc. (VYGR)
CIK:        0001640266
Form:       8-K
Filed at:   2026-07-13T12:44:19+00:00
Accession:  0001104659-26-082906
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Voyager presents positive GLP tox data for tau gene therapy VY1706; plans H2 2026 dosing
--------------------------------------------------------------------------------

- GLP toxicology data for VY1706 showed favorable tolerability in NHPs with no adverse CNS or peripheral findings up to 5x10^13 vg/kg.
- Single IV dose achieved up to 75% lowering of MAPT mRNA and tau protein in key AD brain regions through six months.
- ALPL brain vasculature receptor mediated VY1706 blood-brain barrier transport, supporting cross-species translatability.
- IND clearance received June 2026; multi-site open-label dose-escalation trial to begin dosing in H2 2026.
- Data presented at Alzheimer's Association International Conference on July 13, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1640266/000110465926082906/0001104659-26-082906-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1640266/000110465926082906/tm2620191d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-082906

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer